EMA Updates Guidance in Line With New Pharmacovigilance Legislation

share Share
The European Medicines Agency has revised its procedural guidance for pharmaceutical companies to include the latest information related to the new pharmacovigilance legislation. The guidance for applicants covers pre- and post-authorisation procedures. There are also specific sections for generic, hybrid and biosimilar medicines.

The update concerns all questions and answers on issues affected by the new legislation and its impact on the centralised procedures. In this context, some questions have been either completely revised or added to reflect new procedures introduced by the legislative changes, such as periodic safety update reports (PSURs), post-authorisation safety studies (PASSs) and summaries of the pharmacovigilance master file.

The guidance has been amended to reflect changes to the existing procedures, such as appointment of Pharmacovigilance Risk Assessment Committee (PRAC) rapporteurs and additional milestones as part of the PRAC assessment reflected in updated timetables.

For more information, please visit: www.ema.europa.eu

Published on : Thu, 28 Mar 2013


Print as PDF

Related Articles

COCIR, an organisation representing the European medical imaging, electromedical and healthcare ICT industry, has welcomed Italian... Read more

The ECDC has published a technical report on infection control and hospital hygiene. The intent of ECDC is to propose a comprehensive... Read more

The Health Consumer Powerhouse (HCP) will produce the Euro Pancreatic Cancer Index (EPI), for the first time comparing and analysing... Read more

EU, Pharma The European Medicines Agency has revised its procedural guidance for pharmaceutical companies to include the latest information related to the new pharmac

No comment


Please login to leave a comment...

Highlighted Products